-
Study aim
-
Determination of the effect of supplementation of pms50 on psychological symptoms of premenstrual syndrome
-
Design
-
The present study is a clinical trial of phase 3, randomized, double-blind, and parallel, which will be performed on 50 girls with premenstrual syndrome who have criteria for entering the study. The participants were randomly assigned to dice Two groups of intervention and control will be divided.
-
Settings and conduct
-
This study will be performed on female students of Ahwaz University of Medical Sciences. At first, anthropometric measurements of individuals such as weight, height, BMI, abdomen and Durlegan were measured and a 3-day dietary recall questionnaire and a physical activity questionnaire were recorded. To be The standard Rozgovnol and Bonlander questionnaires were given to individuals, and the questionnaire was followed by a three-day diet.
-
Participants/Inclusion and exclusion criteria
-
Entry criteria: single, premenstrual syndrome, regular menstrual cycle, age range 25-35, weight range 55-65kg, normal BMI ranging from18.5 to 24.9 kg/m2.Exit criteria: Marriage, pregnancy, lactation, irregular menstrual cycle, age below 25 or over 35, weight below 55 or above 65kg, taking psychological drugs andUnwillingness of the participant to continue the research
-
Intervention groups
-
Participants of female students of Ahvaz University of Medical Sciences were selected for premenstrual syndrome. During the three consecutive menstrual cycles, from one week before menstruation to the end of the menstrual cycle, two tablets (one morning and one night), the supplementary intervention group PMS50 and the placebo control group.
-
Main outcome variables
-
Symptoms include restlessness, depression, anger, irritability, transient mood, anxiety and worry, feeling of frustration, loneliness and isolation, feeling unwell, appetite increase or decrease, tenderness to salty or sweet foods